PGDx signs licensing deal with Memorial Sloan Kettering Cancer Center - Technical.ly Baltimore

Sciences

Feb. 28, 2018 12:49 pm

PGDx signs licensing deal with Memorial Sloan Kettering Cancer Center

The deal gives Baltimore-based PGDx intellectual property to bolster its cancer tests.

Pipettes and test tubes.

(Photo by Flickr user Luca Volpi, used under a Creative Commons license)

Personal Genome Diagnostics is adding to its IP portfolio to further develop new kinds of cancer tests.

A licensing deal announced Wednesday gives the Canton-based company exclusive rights to develop and commercialize products based on a key discovery at Memorial Sloan Kettering Cancer Center in New York. Financial terms were not disclosed.

The two entities were both involved in research of a biomarker called tumor mutation status. This measures the number of mutations in a tumor. In a 2015 study published by Memorial Sloan Kettering researchers in the journal Science, patients with more mutations responded to a new form of cancer immunotherapy than those with a tumor with fewer mutations. It suggests that tests could indicate whether certain patients are good candidates for the drugs.

According to a statement from PGDx CEO Doug Ward, the new patents add to existing IP that the company has in the area.

“In 2016 we licensed co-exclusive rights to important intellectual property in this area from Johns Hopkins University and are now pleased to reinforce our IP portfolio by licensing MSK’s complementary patents,” Ward said. “We are confident that the combined patent estate adequately protects our extensive investment and development plans for our TMB-enabling tests.”

The company’s tests are based on work to analyze cancer at the genomic level that began at Johns Hopkins in 2010. It combines gene sequencing and algorithms, as well as new forms of testing. One such test would allow a biopsy to be taken from a blood sample.

The licensing deal comes a little more than a month after PGDx closed a $75 million Series B funding round, and said announced plans to develop the testing to be completed outside a lab. The company is also expanding to a second Baltimore office in Brewers Hill.

-30-
JOIN THE COMMUNITY, BECOME A MEMBER
Already a member? Sign in here

Advertisement

With free glasses, Vision for Baltimore looks to help students see clearly in the classroom

Maryland looks to help Israeli health startups expand to the U.S.

Immunotherapy startup moves into the University of Maryland BioPark

SPONSORED

Baltimore

SmartLogic propels digital transformation aboard Baltimore Water Taxi

Canton

TrackOFF

Junior Marketer

Apply Now
Canton

TrackOFF

IOS/Swift Developer

Apply Now
Canton

TrackOFF

Chief Engineer

Apply Now

A pair of Baltimore biotech companies are getting $36M to create a new vaccine

Yelp will add health inspection info for restaurants around the country

Clear Guide Medical gets $2M grant to develop tools for pediatrics

SPONSORED

Baltimore

Join our Technical.ly Match beta, an opt-in alternative to recruiting

Canton

SmartLogic

Marketing Intern

Apply Now
Baltimore, MD 21201

14 West

Web Developer

Apply Now
Baltimore, MD 21201

14 West

Technical Course Specialist

Apply Now

Sign-up for daily news updates from Technical.ly Baltimore

Do NOT follow this link or you will be banned from the site!